As I wrote in a previous post on the Pharmacogenomics Research Network (PGRN), we have been transitioning our support of pharmacogenomics research from set-aside funding to regular competition with other scientific areas. This is part of the Institute’s efforts to bolster support for investigator-initiated research. We’ll now fund pharmacogenomics research primarily through regular research grant mechanisms, such as R01s or well-justified P01s.
To learn more about how pharmacogenomics-related applications fare in review, our Office of Program Planning, Analysis, and Evaluation conducted an analysis of NIH-wide pharmacogenomics-related applications assigned to Center for Scientific Review study sections. The analysis showed that these applications have comparable success in the review and award processes as applications in other scientific fields. Even so, I still recommend that applicants include a cover letter describing the kinds of expertise they believe are needed for an appropriate review. This can be particularly beneficial for a multidisciplinary research area like pharmacogenomics.
Mike Rogers, who has directed the NIGMS Division of Pharmacology, Physiology, and Biological Chemistry for the past 22 years, retired today. Throughout his NIH career, Mike has been a champion for chemistry and its important role in biomedical research.
Before joining NIGMS 26 years ago, Mike worked for more than a decade in what is now the Center for Scientific Review, where he oversaw the Bioorganic and Natural Products study section.
Between these two positions, Mike completed a detail assignment on Capitol Hill working for Senator Ted Kennedy’s Health, Education, Labor and Pensions Committee, an experience that he says allowed him to see NIH from a different perspective.
Throughout his time at NIGMS, Mike has sought to build scientific bridges. He created the chemistry-biology interface predoctoral training program, which aims to cross-train students in both disciplines. He was instrumental in developing the large-scale collaborative project awards program that “glued” together scientists with diverse expertise to tackle big, unanswered questions in biology. More recently, he forged a link between two fields to help form the new field of quantitative and systems pharmacology. Along the way, he mentored and encouraged others to develop major NIGMS and trans-NIH initiatives, such as those in glycoscience, pharmacogenomics and synthetic organic chemistry.
I am pleased to announce the availability of the new NIGMS strategic plan. This document outlines many of the priorities and activities that the Institute will pursue over the next 5 years. It’s designed as a framework to both codify and focus our efforts, while still allowing us the flexibility to pursue untapped opportunities in areas relevant to our mission.
The plan, which incorporates valuable input from the scientific community, highlights the goals and objectives listed below. It also contains specific implementation strategies for each objective.
- Maximize investments in investigator-initiated biomedical research to drive fundamental scientific discoveries that advance understanding of human health and disease.
- Invest in and sustain a broad and diverse portfolio of highly meritorious research.
- Promote the ability of investigators to pursue new research directions, novel scientific insights and innovative ideas.
- Support the development of a highly skilled, creative and diverse biomedical research workforce.
- Assess Institute research training and education programs and policies to ensure that they achieve positive outcomes related to the NIGMS mission.
- Promote the identification of best practices to continually improve the quality of research training activities.
- Support the development of and access to essential research tools, resources and capabilities for biomedical research.
- Support access to essential research resources and the development of new technologies that enable novel scientific advances.
- Continue the development of institutional research capacities and communities.
- Advance understanding of fundamental biomedical research and the NIGMS role in supporting it.
- Use a broad range of approaches to inform the public about NIGMS goals, activities and results.
- Continue to engage in an open dialogue with the scientific community and other stakeholders about NIGMS programs, processes and policies.
In addition, the plan includes a goal related to the optimization of Institute operations.
Finally, the plan reiterates our commitment to the stewardship of taxpayer funds and an atmosphere of open dialogue, collaboration and shared responsibility with the scientific community. In that spirit, we welcome suggestions to help us become as efficient and effective as possible in the pursuit of our mission.
I recently had the opportunity to talk to Phil Bourne, NIH’s associate director for data science, about some of the current Big Data to Knowledge (BD2K) initiative activities. I asked him how they tie together his vision of a digital enterprise for biomedical research and how they might benefit NIGMS grantees.
Phil explained that the goal of his office, commonly referred to as ADDS, is to achieve efficiencies in biomedical research, such as by making it easier for researchers to locate and manipulate data and software. “If we could just achieve a 5 percent improvement in efficiency in research that would be, in NIH budget dollars, more than $150 million a year that could be spent on funding more people and doing more research,” he said.
An active area that we at NIGMS are engaged in with ADDS is sustaining biomedical data resources, of which we support a fair number. As someone who previously set up databases and who now oversees them, I’m very passionate about this topic. A key question is how to sustain support of data resources in the current research budget environment. Led by Phil’s team, NIH has issued a request for information on sustaining biomedical data repositories that seeks input on every aspect of maintaining these resources. I encourage you to share your ideas by the March 18 response date.
Training is important in Phil’s vision for a digital enterprise, too. He told me of a number of recent training activities at NIH, including a “software carpentry” workshop for experimental researchers to learn how to use a wide variety of analysis tools. In a blog post about this and another event , the ADDS office asks for suggestions on other types of data science courses to offer. They want to provide workshops that train more experimentally versed scientists to work with big data and take those skills back to their labs. In addition, the ADDS office is planning to stand up a workforce development center to catalog classroom and online courses in the data sciences.
Another effort that’s in the works is creating a virtual space called the Commons where researchers can share, locate, utilize and cite datasets, software, standards definitions and documentation. Phil anticipates that the first components of the Commons will be available in 2016.
I’m really excited about Phil’s efforts and believe that they will help drive the “data quantum leap” I described in my first Feedback Loop blog post.
I previously told you about the formation of two committees focused on Protein Structure Initiative (PSI) transition planning. These committees were charged with identifying high priorities for future NIGMS investments in structural biology and determining what unique resources and capabilities developed during the PSI should be preserved to address the needs of the scientific community. Dr. Leemor Joshua-Tor, one of the committee co-chairs, presented the groups’ report at the National Advisory General Medical Sciences Council meeting on January 23.
The committees’ recommendations for preserving PSI resources that the committees felt will be important for the community in the future include:
- Support for a modest number of protein expression resources to serve the needs of the community.
- Continued support for a materials repository similar to the one that has been supported through PSI.
- Possible continued support for a structural biology knowledgebase .
The committees identified these areas as high priorities for the future of structural biology:
- Continued support for synchrotron beamlines for crystallography.
- Support for modern cryo-EM resource centers.
- Continued support for NMR resources for structural biology.
- Support for the integration of structural biology methods.
- Support for collaborative, multi-investigator efforts in membrane protein and large macromolecular assembly structure determination.
We’re now developing plans for implementing the report’s recommendations.
Jon Lorsch recently posted a message about the responsibility that our grantee community shares with us to help the research enterprise thrive. One way that we have addressed this is by taking a hard look at the funding of investigators who are already well supported. As most of you know, in an effort to increase efficiency and to support as many outstanding scientists as possible, we have long required special advisory council approval for any grant that, in combination with the principal investigator’s (PI’s) other research support, would provide over $750,000 in direct costs.
We have now developed guidelines that we will use in awarding R01s and other research grants to investigators with substantial levels of long-term, unrestricted research funding from any source. Unrestricted funding means that it is not project-based and may be used to conduct research on a broad topic at the PI’s discretion. We consider such support substantial and long-term if it is over $400,000 in direct costs (excluding the PI’s salary and direct support of widely shared institutional resources) and extends for at least 2 years from the time the NIGMS grant would be funded.
Abiding by these new guidelines will enable us to fund additional labs, increasing the likelihood of making significant scientific advances. The guidelines will take effect for applications submitted on or after January 2, 2016. If you might be affected by the new guidelines, I encourage you to discuss your plans with your program director.
Using a technique made possible by super-resolved fluorescence microscopy, scientists captured this image of a cellular skeleton. More details
We were excited to learn this morning that our grantee William E. Moerner will share the 2014 Nobel Prize in chemistry with Eric Betzig and Stefan W. Hell "for the development of super-resolved fluorescence microscopy." We congratulate them on this well-deserved recognition of their pioneering work, which has provided an unprecedented window into the cell and paved the way for understanding a range of biological processes.
I’m particularly thrilled with today’s news because it highlights an NIGMS-supported field that I’ve been closely involved in for more than 15 years. I remember my first conversation with W.E. on moving single-cell spectroscopy into biology, which led to a 2000 workshop we held to explore the state of the art in—and potential for—research in single molecule detection and manipulation. The recommendations from that workshop informed the development of a number of initiatives to apply the tools and approaches of the physical sciences to biological problems. The initiatives include our single molecule detection and manipulation program announcement and an NIH Roadmap for Medical Research program on the development of high-resolution probes for cellular imaging.
Since then, we have witnessed an explosion in the use of optical methods to look at single molecules at the nanoscale level and are gaining a wealth of insights as a result.
A statement from NIGMS on the prize is at http://www.nigms.nih.gov/news/results/pages/20141008.aspx. More information about our support of Nobel Prize winners is at http://www.nigms.nih.gov/education/pages/factsheet_NIGMSNobelists.aspx and at http://www.nigms.nih.gov/pages/GMNobelists.aspx.
The National Synchrotron Light Source (NSLS) at Brookhaven National Laboratory (BNL) closed earlier this week as a newer, more advanced facility, NSLS-II , began to come online.
Thousands of NIH researchers have used beamlines at NSLS over the last 30 years to collect data to characterize biological macromolecules including drug targets, ion pumps and enzymes. Because the beamlines for biological research at NSLS-II will not be available until 2016, other synchrotron facilities are temporarily expanding their capacity to address the beamline reduction.
Here are some sources that will help you identify and access beamlines at other U.S. synchrotrons:
If you have questions about NIH-funded synchrotron resources, please contact me or Ward Smith.